Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company whose news flow centers on its portfolio of FDA-approved brands and its clinical development programs. The company focuses on hospital acute care, gastroenterology, and oncology markets, and its announcements often highlight product milestones, commercialization agreements, and study results that affect how its medicines are used in practice.
Recent news has covered developments for Caldolor (ibuprofen) injection, including a permanent CMS J-code associated with a reimbursement price that supports its use as a non-opioid option for managing pain and fever. Cumberland has also reported regulatory approval of its ibuprofen injection product in Mexico through a partnership with PiSA Farmaceutica, reflecting the company’s efforts to expand access to its hospital acute care therapies internationally.
Another recurring theme in CPIX news is the expansion of Vibativ (telavancin) injection. Press releases describe new supply arrangements and group purchasing agreements with organizations such as Vizient and Premier in the United States, as well as the launch of Vibativ in Saudi Arabia through Tabuk Pharmaceutical Manufacturing Company. These updates explain how hospitals and providers can access Vibativ in different configurations and markets.
Cumberland’s news also highlights its ifetroban Phase II clinical programs in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis, including presentations of trial data and regulatory interactions. In addition, investors can follow revenue updates and quarterly financial results, which break down net revenues by product such as Kristalose, Sancuso, Vibativ, and Caldolor.
For readers tracking CPIX, the news stream provides insight into product-level performance, international partnerships, reimbursement developments, and the progress of late-stage clinical studies. Bookmarking this page can help investors, clinicians, and other stakeholders follow key events affecting Cumberland’s commercial portfolio and pipeline.
Cumberland Pharmaceuticals (Nasdaq: CPIX) launched an updated Sancuso website on March 17, 2026, offering educational resources for chemotherapy-induced nausea and vomiting (CINV).
The site highlights Sancuso as the only prescription granisetron transdermal patch approved by the FDA to prevent CINV for up to five days, and includes clinical data, HCP tools, patient education, and prescribing information.
H. pylori infections market (CPIX) is projected to expand from a USD 270 million market in 2025 at a 9.4% CAGR through 2036 across the 6MM. US holds ~85% of 2025 revenue and ~57 million diagnosed prevalent cases; emerging therapies such as rifasutenizol, linaprazan glurate, and tegoprazan are expected to reshape treatment paradigms with reported Phase III eradication rates >90% for some candidates.
Challenges include a limited pipeline, geographic regulatory gaps, rising antibiotic resistance, and adherence issues with high pill burdens.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q4 2025 combined net revenues of $13.7M, up 31% year-over-year, and full-year 2025 net revenues of $44.5M, up 18% versus 2024. The company posted a $2.9M net loss for 2025 and $1.7M adjusted earnings. Total assets were $76.8M and shareholders' equity was $24.9M at year end.
Key developments: international launches/approvals, Talicia co-commercialization, permanent J-code for Caldolor, positive FIGHT DMD Phase II topline results and FDA fast track designation in early 2026.
Cumberland Pharmaceuticals (Nasdaq: CPIX) launched a national U.S. sales promotion for Talicia on Feb 25, 2026, under a co-commercialization agreement with RedHill Biopharma.
Talicia is an FDA-approved, all-in-one oral capsule for H. pylori, patent protected through 2042 with eight years of U.S. market exclusivity under QIDP; Cumberland will use its field sales force to expand prescriptions and patient access.
RedHill (Nasdaq:RDHL) and Cumberland (Nasdaq:CPIX) have begun the full U.S. sales and operational launch of Talicia under Talicia Holdings Inc. (THI), a 70/30 RedHill/Cumberland joint operating entity. Cumberland made a $4 million strategic investment and the joint model launched after an October 2025 agreement.
Talicia is positioned as the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy, is patent-protected through 2042, holds eight years of U.S. market exclusivity (QIDP), and targets an estimated 1.6 million U.S. patients treated annually.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will report its 2025 annual financial results and provide a company update after market close on March 3, 2026. A conference call is scheduled for March 3 at 4:30 p.m. ET with a replay available for one year.
The company highlighted its FDA-approved hospital, gastroenterology and oncology portfolio and noted ongoing Phase II trials for ifetroban in systemic sclerosis, DMD cardiomyopathy and idiopathic pulmonary fibrosis.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced that the FDA granted Fast Track Designation for oral ifetroban to treat Duchenne muscular dystrophy (DMD) heart disease on Feb 4, 2026. This follows prior Orphan Drug and Rare Pediatric Disease designations and builds on Phase 2 FIGHT DMD results showing a 5.4% LVEF improvement over 12 months.
The Fast Track status enables more frequent FDA interactions and rolling submission options to potentially accelerate review for this urgent, unmet pediatric cardiac indication.
Cumberland Pharmaceuticals (Nasdaq: CPIX) announced on Dec 8, 2025 that Caldolor® (ibuprofen) Injection's permanent J-code J1741 is now officially associated with a reimbursement price, creating a CMS-covered, non-opioid option for pain and fever management.
The update links an established reimbursement price to J1741, which the company says supports opioid-sparing strategies, encourages providers to update billing systems, and may improve access to Caldolor for adult and pediatric patients where ibuprofen is indicated.
Cumberland Pharmaceuticals (Nasdaq: CPIX) reported third-quarter 2025 net revenues of $8.3 million and year-to-date net revenues of $30.8 million, a 12% increase versus the first nine months of 2024. The company ended the quarter with approximately $66 million in total assets, $40 million in liabilities and $26 million of shareholders' equity, including $15 million in cash.
Recent developments include a co-commercialization and 30% ownership stake in newly formed Talicia Holdings (Talicia), international launches and approvals for Vibativ and an ibuprofen injection, inclusion of Vibativ in Vizient and Premier purchasing arrangements, and ongoing Phase II ifetroban programs with positive FIGHT DMD findings submitted to the FDA.
Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its third quarter 2025 financial results and provide a company update after market close on Tuesday, Nov. 4, 2025. A conference call to discuss results is scheduled for Nov. 4 at 4:30 p.m. ET. Participants must register online to receive dial‑in/PIN details or use a "Call Me" option. A replay will be available for one year via the company's Investor Relations page or the provided media-server link.
The company is a specialty pharmaceutical firm with FDA‑approved hospital and oncology products including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ, and is running Phase II trials of ifetroban in systemic sclerosis, DMD cardiomyopathy, and idiopathic pulmonary fibrosis. For full prescribing information and product links visit the company website.